TherapeuticsMD
TXMD
154 hedge funds and large institutions have $204M invested in TherapeuticsMD in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 49 increasing their positions, 38 reducing their positions, and 23 closing their positions.
133% more call options, than puts
Call options by funds: $2.01M | Put options by funds: $865K
29% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 38
0.04% less ownership
Funds ownership: 0.91% → 0.87% (-0.04%)
4% less funds holding
Funds holding: 160 → 154 (-6)
14% less capital invested
Capital invested by funds: $237M → $204M (-$33.1M)
26% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.49M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$2.39M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.2M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.46M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$761K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$3.69M |
| 2 |
BlackRock
New York
|
-$3.34M |
| 3 |
Axa
Paris,
France
|
-$2.59M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$2.19M |
| 5 |
Goldman Sachs
New York
|
-$1.91M |
TXMD Hedge Fund Activity: Q2 2021 in Review
154 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q2 2021, worth a combined $204M — down 14% from $237M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of TXMD and 17 opened new positions — a net loss of 6 holders — while 38 trimmed existing stakes and 49 added.
The largest buyer was Morgan Stanley, adding an estimated $3.49M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $3.69M sold.
- 154 institutional investors held TherapeuticsMD (TXMD) as of Q2 2021, down from 160 in Q1 2021.
- Funds reported $204M of TherapeuticsMD stock for Q2 2021, down 14% quarter-over-quarter.
- 17 funds opened new TherapeuticsMD positions in Q2 2021 and 23 closed out, a net change of -6 holders.
- The largest TherapeuticsMD buyer in Q2 2021 was Morgan Stanley, an estimated $3.49M added.
- The largest TherapeuticsMD seller in Q2 2021 was Perceptive Advisors, an estimated $3.69M sold.
Based on aggregated 13F filings for Q2 2021.